Answer
Jan 15, 2026 - 11:02 AM
Kombiglyze (saxagliptin and metformin) was discontinued in some markets primarily due to commercial reasons, such as low demand and the availability of alternative diabetes medications. There were also concerns about potential side effects, but regulatory agencies did not mandate its withdrawal for safety reasons.
